Background and Purpose: Ischaemic visual loss is often considered a lower risk factor than other transient ischaemic attacks (TIA). We aimed to determine the recurrence risk, prevalence and management of vascular risk factors in these patients. Methods: The study took place in the University College Hospital London daily TIA clinic, main referral centre for North-Central London and Moorfields Eye Hospital. Consecutive records for patients with transient (< 24 h) or permanent (> 24 h) ischaemic visual loss were reviewed during the period January 2014–October 2016. Patients diagnosed with temporal arteritis were excluded. Results: Of 400 patients, 224 (56%) were male with mean age 64.5 years (SD 15.1); 263 patients (65.8%) presented with transient and 137 patients (34.2%) with permanent ischaemic visual loss; 51.3% had hypertension (HTN), 35.3% hypercholesterolaemia, 14.5% diabetes, 11.8% ischaemic ocular events, 10.0% ischaemic heart disease, 7.3% atrial fibrillation (AF), 6.3% TIA, 5.3% stroke, and 12.3% were smokers. Median vascular risk factors were 2 (range 1–6), but 122 (30.5%) had ≥3. Those with diabetes (p < 0.001), HTN (p = 0.008), previous myocardial infarction (p = 0.005), or ≥3 vascular risk factors (p = 0.012) were more likely to present with permanent visual loss, while patients with history of transient events, TIA (p = 0.002), or ocular (p = 0.002) presented with transient visual loss. Ninety-day recurrence was 10.5%; this was higher in patients with ≥3 risk factors (hazard ratio 1.42, 95% CI 0.95–2.11, p = 0.111). Patients with past TIA were more likely to be on secondary prevention than those with ocular ischaemia; 60.0 vs. 34.1% received antiplatelets and 76.0 vs. 43.9% statins. At presentation, only 55.2% (16 patients) with known AF were anticoagulated, despite all of them having CHADSVASC ≥1. Conclusions: Approximately one-third of patients with ocular ischaemia had ≥3 vascular risk factors with recurrences higher in these patients. Yet only half of those with previous ischaemic ocular events were on antiplatelets or statins. These patients should be investigated and treated as aggressively as other forms of TIA or stroke.

Keywords:
Transient monocular visual loss, Vascular risk factors, Secondary prevention
1.
Hayreh SS: Acute retinal arterial occlusive disorders. Prog Retin Eye Res 2011; 30: 359–394.
2.
Hurwitz BJ, Heyman A, Wilkinson WE, Haynes CS, Utley CM: Comparison of amaurosis fugax and transient cerebral ischemia: a prospective clinical and arteriographic study. Ann Neurol 1985; 18: 698–704.
3.
Hankey GJ, Slattery JM, Warlow CP: Transient ischaemic attacks: which patients are at high (and low) risk of serious vascular events? J Neurol Neurosurg Psychiatry 1992; 55: 640–652.
4.
Benavente O, Eliasziw M, Streifler JY, Fox AJ, Barnett HJ, Meldrum H; North American Symptomatic Carotid Endarterectomy Trial Collaborators: Prognosis after transient monocular blindness associated with carotid-artery stenosis. N Engl J Med 2001; 345: 1084–1090.
5.
Pancioli AM, Broderick J, Kothari R, Brott T, Tuchfarber A, Miller R, Khoury J, Jauch E: Public perception of stroke warning signs and knowledge of potential risk factors. JAMA 1998; 279: 1288–1292.
6.
Yoon SS, Byles J: Perceptions of stroke in the general public and patients with stroke: a qualitative study. BMJ 2002; 324: 1065–1068.
7.
Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S: Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369: 283–292.
8.
Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35–41.
9.
Park SJ, Choi NK, Yang BR, et al: Risk and risk periods for stroke and acute myocardial infarction in patients with central retinal artery occlusion. Ophthalmology 2015; 122: 2336–2343.
10.
Donders RC: Clinical features of transient monocular blindness and the likelihood of atherosclerotic lesions of the internal carotid artery. J Neurol Neurosurg Psychiatry 2001; 71: 247–249.
11.
Hankey GJ, Slattery JM, Warlow CP: Prognosis and prognostic factors of retinal infarction: a prospective cohort study. BMJ 1991; 302: 499–504.
12.
De Schryver EL, Algra A, Donders RC, van Gijn J, Kappelle LJ: Type of stroke after transient monocular blindness or retinal infarction of presumed arterial origin. J Neurol Neurosurg Psychiatry 2006; 77: 734–738.
13.
Rim TH, Han J, Choi YS, Hwang SS, Lee CS, Lee SC, Kim SS: Retinal artery occlusion and the risk of stroke development: twelve-year Nationwide Cohort Study. Stroke 2016; 47: 376–382.
14.
Volkers EJ, Donders RCJM, Koudstaal PJ, van Gijn J, Algra A, Kappelle LJ: Transient monocular blindness and the risk of vascular complications according to subtype: a prospective cohort study. J Neurol 2016; 263: 1771–1777.
15.
Purroy F, Montaner J, Molina CA, Delgado P, Ribo M, Alvarez-Sabín J: Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke 2007; 38: 3225–3229.
16.
Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, et al; Early use of Existing Preventive Strategies for Stroke (EXPRESS) Study: Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke -(EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370: 1432–1442.
17.
Kvickström P,Lindblom B, Bergström G, Zetterberg M: Amaurosis fugax – delay between symptoms and surgery by specialty. Clin Ophthalmol 2016; 10: 2291–2296.
18.
Hsu HY, Yang FY, Chao AC, Chen YY, Chung CP, Sheng WY et al: Distribution of carotid arterial lesions in Chinese patients with transient monocular blindness. Stroke 2006; 37: 531–533.
19.
Zhang LY, Zhang J, Kim RK, Matthews JL, Rudich DS, Greer DM, Lesser RL, Amin H: Risk of acute ischemic stroke in patients with monocular vision loss of vascular etiology. J Neuroophthalmol 2018, Epub ahead of print.
20.
Golsari A, Bittersohl D, Cheng B, Griem P, Beck C, Hassenstein A, Nedelmann M, Magnus T, Fiehler J, Gerloff C, Thomalla G: Silent brain infarctions and leukoaraiosis in patients with retinal ischemia: a prospective single-center observational study. Stroke 2017; 48: 1392–1396.
21.
Seet RC, Friedman PA, Rabinstein AA: Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 2011; 124: 477–486.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.